Global Female Sexual Dysfunction Treatment Market Size study & Forecast, by Type( Arousal Disorder, Penetration Disorder, Female Orgasmic Disorder) by Therapy( Estrogen Therapy, Androgen Therapy and Others), by Age( 25 Years, 25-40 Years and Above 40 Yea

Global Female Sexual Dysfunction Treatment Market Size study & Forecast, by Type( Arousal Disorder, Penetration Disorder, Female Orgasmic Disorder) by Therapy( Estrogen Therapy, Androgen Therapy and Others), by Age( 25 Years, 25-40 Years and Above 40 Years.), and Regional Analysis, 2022-2029

Global Female Sexual Dysfunction Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Sexual dysfunction is a psychiatric condition characterized by a persistent or recurrent inability to elicit sexual excitement. The Female Sexual Dysfunction Treatment market is expanding because of factors such as increasing incidences of sexual dysfunction among women, rise in the adoption of an unhealthy lifestyle and increase in consumption of alcohol among women.

Rising prevelance of sexual dysfunction among women is driving the market growth. Data from the Blue Cross Blue Shield Association, a federation of 36 different US health insurance firms, showed that approximately 43% of American women were thought to experience female sexual dysfunction on a yearly basis. Furthermore, Safety label changes for female sexual dysfunction therapy and rise in product development activities will accelerate market growth during the forecast period. For instance, in April 2019, US FDA issued a safety labelling change order to Sprout Pharmaceuticals, which needs the company to revise the safety information for Addyi. Similarly, in year 2018, The U.S. Food and Drug Administration (FDA) has approved the use of bremelanotide, a first-in-class melanocortin 4 receptor agonist, to treat premenopausal women with hypoactive sexual desire disorder (HSDD). Moreover, Rise in awareness of the treatment and prevelance of chronic illness among the women is creating a lucrative growth to the market. However, lack of standardization in the treatment of sexual dysfunction stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Female Sexual Dysfunction Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Apricus Biosciences, Inc
GlaxoSmithKline, plc.
Pfizer, Inc.
AMAG Pharmaceuticals
Merck & Co., Inc.
Cipla Inc.
Duchesnay Inc.,
Sprout Pharmaceuticals Inc.
Novo Nordisk AS,
Strategic Science and Technologies LLC

Recent Developments in the Market:
 In June 2019, the US Food and Drug Administration approved Vyleesi (bremelanotide) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
 In June 2018, Pivot Pharmaceuticals Inc. submitted the Clinical Trial Application (CTA) with Health Canada and the Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to start human clinical trials for PVT-005 for the treatment of Female Hypoactive Sexual Desire Disorder (HSDD).

Global Female Sexual Dysfunction Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Therapy, Age, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Typeofferings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Arousal Disorder
Penetration Disorder
Female Orgasmic Disorder
By Therapy:
Estrogen Therapy
Androgen Therapy
Others
By Age:
25 Years
25-40 Years
Above 40 Years.

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Apricus Biosciences, Inc
GlaxoSmithKline, plc.
Pfizer, Inc.
AMAG Pharmaceuticals
Merck & Co., Inc.
Cipla Inc.
Duchesnay Inc.,
Sprout Pharmaceuticals Inc.
Novo Nordisk AS,
Strategic Science and Technologies LLC


Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.